Table 2 Absolute values and relative change in comparator (bold text) and investigational parameters (mean ± SD)
| Â | Parameter | Group | Initial | Follow-up | Change (%) |
|---|---|---|---|---|---|
CMR-derived | RVEF (%) | PAH | 41 ± 17 | 43 ± 13 | 18 ± 47 |
High risk | 60 ± 7 | 59 ± 6 | −1 ± 13 | ||
RVESVI (ml/m 2) | PAH | 50 ± 26 | 54 ± 25 | 17 ± 49 | |
High risk | 24 ± 7 | 25 ± 8 | 4 ± 19 | ||
meanPAvel at rest (cm/s) | PAH | 9.7 ± 2.3 | 10.0 ± 3.0 | 5 ± 27 | |
High risk | 14.4 ± 2.6 | 13.9 ± 3.6 | −4 ± 23 | ||
meanPAvel during hyperemia (cm/s) | PAH | 12.2 ± 3.3 | 12.9 ± 6.3 | 6 ± 32 | |
High risk | 21.5 ± 4.3 | 19.8 ± 4.9 | −8 ± 8 | ||
RVEDVI (ml/m2) | PAH | 84 ± 19 | 91 ± 22 | 8 ± 15 | |
High risk | 61 ± 14 | 61 ± 17 | 0 ± 13 | ||
LVEF (%) | PAH | 65 ± 11 | 68 ± 9 | 5 ± 21 | |
High risk | 69 ± 4 | 66 ± 6 | −3 ± 9 | ||
RHC-derived | CI (L/min/m 2) | PAH | 2.35 ± 0.76 | 2.59 ± 0.81 | 13 ± 19 |
High risk | 2.80 ± 0.55 | n/a | n/a | ||
PVRI (WU/m 2) | PAH | 5.5 ± 3.2 | 5.3 ± 3.4 | 11 ± 47 | |
High risk | 1.0 ± 0.4 | n/a | n/a | ||
mPAP (mmHg) | PAH | 46 ± 16 | 48 ± 14 | 9 ± 24 | |
High risk | 19 ± 4 | n/a | n/a | ||
mPAWP (mmHg) | PAH | 10 ± 2 | 8 ± 5 | 3 ± 30 | |
High risk | 10 ± 3 | n/a | n/a | ||
Clinical/Biomarker | NTpBNP (pg/ml) | PAH | 2310 ± 1354 | 2740 ± 1361 | 71 ± 200 |
High risk | 1345 ± 718 | 1289 ± 693 | −3 ± 13 | ||
6MWD (m) | PAH | 421 ± 81 | 435 ± 62 | 7 ± 18 | |
High risk | 484 ± 71 | 437 ± 94 | −3 ± 8 |